7 news items
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
Roche; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
ALNY
11 Mar 24
in the areas of corporate, securities, and antitrust class litigation. Founded by the late
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
ALNY
7 Mar 24
Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
ALNY
5 Mar 24
; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed
wzbvgsb17nfxbf82 y0arqn149nac2yha521dd95mroz6l
ALNY
3 Mar 24
of corporate, securities, and antitrust class litigation. Founded by the late Abraham L
aap1mg5zaabpspkcrh1eb7o62sg
ALNY
28 Feb 24
litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions
- Prev
- 1
- Next